Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
ARS PHARMACEUTICALS INC (SPRY) Stock Price & Overview
NASDAQ:SPRY • US82835W1080
Current stock price
7.725 USD
-0.22 (-2.71%)
Last:
The current stock price of SPRY is 7.725 USD. Today SPRY is down by -2.71%. In the past month the price increased by 1.6%. In the past year, price decreased by -45.09%.
SPRY Key Statistics
52-Week Range6.66 - 18.9
Current SPRY stock price positioned within its 52-week range.
1-Month Range7.72 - 8.56
Current SPRY stock price positioned within its 1-month range.
- Market Cap
- 767.093M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.75
- Dividend Yield
- N/A
SPRY Stock Performance
Today
-2.71%
1 Week
+1.28%
1 Month
+1.60%
3 Months
-20.52%
Longer-term
6 Months -11.38%
1 Year -45.09%
2 Years -8.74%
3 Years +22.15%
5 Years N/A
10 Years N/A
SPRY Stock Chart
SPRY Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SPRY. When comparing the yearly performance of all stocks, SPRY is a bad performer in the overall market: 91.17% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
SPRY Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SPRY. SPRY has a bad profitability rating. Also its financial health evaluation is rather negative.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
SPRY Earnings
On March 9, 2026 SPRY reported an EPS of -0.42 and a revenue of 28.09M. The company beat EPS expectations (6.77% surprise) and beat revenue expectations (7.63% surprise).
Next Earnings DateMay 19, 2026
Last Earnings DateMar 9, 2026
PeriodQ4 / 2025
EPS Reported-$0.42
Revenue Reported28.087M
EPS Surprise 6.77%
Revenue Surprise 7.63%
SPRY Forecast & Estimates
12 analysts have analysed SPRY and the average price target is 27.2 USD. This implies a price increase of 252.1% is expected in the next year compared to the current price of 7.725.
For the next year, analysts expect an EPS growth of 9.2% and a revenue growth 89.49% for SPRY
Analysts
Analysts88.33
Price Target27.2 (252.1%)
EPS Next Y9.2%
Revenue Next Year89.49%
SPRY Index Membership
SPRY is currently included in the following stock indexes tracked on ChartMill.
SPRY Financial Highlights
Over the last trailing twelve months SPRY reported a non-GAAP Earnings per Share(EPS) of -1.75. The EPS decreased by -3600% compared to the year before.
Income Statements
Revenue(TTM)84.28M
Net Income(TTM)-171.30M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -52.28% | ||
| ROE | -149.92% | ||
| Debt/Equity | 0.84 |
Chartmill High Growth Momentum
EPS Q2Q%-185.71%
Sales Q2Q%-67.56%
EPS 1Y (TTM)-3600%
Revenue 1Y (TTM)-5.46%
SPRY Ownership
Ownership
Inst Owners84.97%
Shares99.30M
Float74.38M
Ins Owners11.8%
Short Float %35.98%
Short Ratio18.37
SPRY Industry Overview
SPRY operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
14/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
66%
Outperformed 66% of sub-industries
3 Month Rank
48%
Outperformed 48% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.8%
- New Lows
- 3.1%
- Average ROE
- 48.3%
- Average Profit Margin
- 20.9%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.2
- Average Fwd P/E
- 22.5
- Average Debt/Equity
- 2.1
SPRY Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.45 | 349.666B | ||
| AMGN | AMGEN INC | 14.68 | 183.263B | ||
| GILD | GILEAD SCIENCES INC | 14.55 | 160.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.7 | 109.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.6 | 77.363B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.3 | 40.311B | ||
| INSM | INSMED INC | N/A | 29.127B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.701B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 11.78 | 26.913B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 24.944B | ||
| INCY | INCYTE CORP | 10.68 | 19.451B | ||
| MRNA | MODERNA INC | N/A | 18.695B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SPRY
Company Profile
ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. The company is headquartered in San Diego, California and currently employs 158 full-time employees. The company went IPO on 2020-12-04. The firm is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Company Info
IPO: 2020-12-04
ARS PHARMACEUTICALS INC
11682 El Camino Real, Suite 300
San Diego CALIFORNIA US
Employees: 158
Phone: 18009279800
ARS PHARMACEUTICALS INC / SPRY FAQ
Can you describe the business of ARS PHARMACEUTICALS INC?
ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. The company is headquartered in San Diego, California and currently employs 158 full-time employees. The company went IPO on 2020-12-04. The firm is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Can you provide the latest stock price for ARS PHARMACEUTICALS INC?
The current stock price of SPRY is 7.725 USD. The price decreased by -2.71% in the last trading session.
Does ARS PHARMACEUTICALS INC pay dividends?
SPRY does not pay a dividend.
How is the ChartMill rating for ARS PHARMACEUTICALS INC?
SPRY has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is ARS PHARMACEUTICALS INC (SPRY) stock traded?
SPRY stock is listed on the Nasdaq exchange.
Can you provide the number of employees for ARS PHARMACEUTICALS INC?
ARS PHARMACEUTICALS INC (SPRY) currently has 158 employees.
What is the next earnings date for SPRY stock?
ARS PHARMACEUTICALS INC (SPRY) will report earnings on 2026-05-19, after the market close.